申请人:Aspnes Gary Erik
公开号:US20120202834A1
公开(公告)日:2012-08-09
The present invention provides a compound of Formula (I)
or a pharmaceutically acceptable salt thereof wherein R
1
, R
2
, R
3
, A
1
, A
2
, A
3
, A
4
, L, B
1
, B
2
, B
3
and B
4
are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.
本发明提供了一种式(I)的化合物或其药学上可接受的盐,其中R1、R2、R3、A1、A2、A3、A4、L、B1、B2、B3和B4如本文所定义。已发现式I的化合物可作为葡萄糖胰高血糖素拮抗剂或逆向激动剂。因此,式I的化合物及其药物组成物对于治疗由葡萄糖胰高血糖素介导的疾病、紊乱或症状是有用的。